| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22051 |
| Drug | Rimegepant |
| Brand | Vydura® |
| Indication | For the acute treatment of migraine with or without aura in adults; and for the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month. |
| Assessment Process | |
| Rapid review commissioned | 13/07/2022 |
| Rapid review completed | 12/09/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of rimegepant (Vydura®) compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 28/09/2022 |
| Pre-submission consultation with Applicant | 10/11/2022 |
| Full submission received from Applicant | 07/02/2023 |
| Preliminary review sent to Applicant | 27/03/2023 |
| NCPE assessment re-commenced | 18/04/2023 |
| Factual accuracy sent to Applicant | 03/05/2023 |
| NCPE assessment re-commenced | 10/05/2023 |
| NCPE assessment completed | 18/05/2023 |
| NCPE assessment outcome | The NCPE recommends that rimegepant (Vydura®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments and that a managed access programme is introduced*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
